Japanese 
English 
Protein-protein interaction network is invaluable resource for the identification of a promising target for PPI drug research and development. Owing to the human genome sequencing and proteome analyses as well as the data science companies and organizations, we have rich access to PPI databases to figure out a candidate interaction to deeply investigate for a better treatment of diseases of worldwide interest.
But still, it’s a kind of “mystery” to find the best one for a particular disease remedy from the myriad of PPI network. That’s what we are currently interested and allocating resources and efforts to bridge PPI and disease to identify the very target for drug development.
Human interactome map has been a huge interest among the pharmaceutical scientists and biologist since the whole human genome sequencing.
The Cell paper in 2005 is probably the starting point and trigger the intense research on genome and proteome analyses and visualization.1) Protein-protein interaction mapping is currently usable in lots of PPI databases and it’s helping us without doubt.
However, these maps do not directly display us the disease-related interactions. In order to figure out a validated target for drug development, a tremendous effort of talented researchers for the specific interaction is a must.
Computational approaches are obviously changing the state. The Cell paper in 2017 threw a huge effort on cancer gene product analyses in an unbiased manner and demonstrated the usefulness of the author’s systematic binary map approach to identify the candidate interactions.2) But there is still a difficulty in reasonable connection of a specific biomolecule interaction to a particular disease.
In a Nature Technology Feature article in 2017 is saying “Improvements in mapping protein–protein interactions are allowing researchers to deconstruct the delicate mechanics of cells.”3) That’s, we think, true considering the data technology development over a decade.
Big data analyses with the aid of artificial intelligence are currently widely used in any field. We deeply appreciate the contribution in PPI network analyses and interactome mapping technology developments.
We would willingly throw continuous efforts on this field so that our partners and ourselves to provide better therapeutic choices for the patients. Those who are interested in peptidomimetics for research, please contact us to discuss the possibility of useful technology/methodology development.
1) https://doi.org/10.1016/j.cell.2005.08.029
2) https://doi.org/10.1016/j.cell.2014.10.050
3) https://doi.org/10.1038/549293a